Previous 10 | Next 10 |
Ultragenyx Pharmaceutical (RARE): Q3 GAAP EPS of -$1.13 beats by $0.15.Revenue of $81.5M (+215.9% Y/Y) beats by $25.66M.Press Release For further details see: Ultragenyx Pharmaceutical EPS beats by $0.15, beats on revenue
Third quarter 2020 total revenue of $ 81.5 million and Crysvita 1 revenue of $37.3 million I ncreased lower end of Crysvita 1 g uidance range ; updated full year range is $130 million to $140 million Doj...
Ultragenyx Pharmaceutical (RARE) and its collaborating partner , GeneTx Biotherapeutics, have reported interim data from the Phase 1/2 study evaluating GTX-102 in Angelman syndrome.Though according to the interim data from the first five patients treated indicate, substantial improvement...
Efficacy in multiple functional measures observed in all five patients treated Highe st doses associated with a significant but reversible safety issue Study amendment planned to focus on lower end of dose range ...
Ultragenyx Pharmaceutical (NASDAQ:RARE) is scheduled to announce Q3 earnings results on Tuesday, October 27th, after market close.The consensus EPS Estimate is -$1.28 (+34.7% Y/Y) and the consensus Revenue Estimate is $55.84M (+116.4% Y/Y).Over the last 1 year, RARE has beaten EPS estimates 5...
4 Penny Stocks To Watch Before Next Week Whether you’re looking for penny stocks to buy or just putting a watch list together, you’ve got one thing in mind: making money. But how can you make money in penny stocks? The answer, while simple, isn’t always the easi...
Ultragenyx Pharmaceutical and Solid Biosciences have entered a collaboration and license agreement to focus on the development and commercialization of new gene therapies for Duchenne muscular dystrophy.Solid has granted Ultragenyx an exclusive license for any pharmaceutical product that expr...
- Collaboration combines Solid’s differentiated microdystrophin construct and Ultragenyx’s HeL a PCL manufacturing platform for use with AAV8 and variants - - Solid receives $40 million upfront via equity investment a...
NOVATO, Calif. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference c...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. While overall market breadth remains narrow, the Strategy...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...